Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Methionine enkephalin - Immune Therapeutics

Drug Profile

Methionine enkephalin - Immune Therapeutics

Alternative Names: INNO-105; IRT-101; IRT-102; MENK; Met-enkephalin; OGF; Opioid growth factor

Latest Information Update: 15 May 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Nonindustrial source
  • Developer Cytocom; Hubei Qianjiang Pharmaceutical; Immune Therapeutics; Penn State College of Medicine
  • Class Antivirals; Enkephalins; Essential amino acids; Opioid peptides; Small molecules
  • Mechanism of Action Immunomodulators; Immunostimulants; Opioid growth factor receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II HIV infections; Liver cancer; Ovarian cancer; Pancreatic cancer
  • No development reported Solid tumours
  • Discontinued Influenza virus infections

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for clinical-Phase-Unknown development in Solid-tumours in China (IV)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Pancreatic-cancer(Combination therapy, First-line therapy, Late-stage disease) in USA (IV)
  • 27 Jun 2017 Immune Therapeutics plans to complete GLP-toxicology studies by the end of fourth quarter of 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top